LKM1 antibody and interferon therapy in children with chronic hepatitis C [3]

Journal of Hepatology

Volumn 35, Issue 5, 2001, Pages 685-687

  Iorio, Raffaele ^a   Giannattasio, Antonietta ^a   Vespere, Giuliana ^a   Vegnente, Angela ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; CYTOCHROME P450 2D6; HLA DQ ANTIGEN; INTERFERON; LIVER KIDNEY MICROSOMAL ANTIBODY TYPE 1; MICROSOME ANTIBODY; RECOMBINANT ALPHA2B INTERFERON; UNCLASSIFIED DRUG;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; AUTOIMMUNITY; CLINICAL ARTICLE; CROSS REACTION; FEMALE; FOLLOW UP; HEPATITIS C; HUMAN; ITALY; LETTER; LIVER INJURY; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; REMISSION; SCHOOL CHILD; VIREMIA;

EID: 0035174983     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0168-8278(01)00195-7     Document Type: Letter

References (8)

1. LKM antibody: Getting in some target practice
2. Autoimmunity and extrahepatic manifestations in hepatitis infection
3. Low virological response to interferon in children with chronic hepatitis C
4. Interferon therapy in LKM-1 positive patients with chronic hepatitis C: Follow-up by a quantitative radioligand assay for CYP2D6 antibody detection
5. Interferon therapy in liver/kidney microsomal antibody type 1-positive patients with chronic hepatitis C
6. LKM-1 autoantibodies recognize a short linear sequence in P450IID6, a cytochrome P-450 monooxygenase
7. Liver/kidney microsomal antibody type 1 targets CYP2D6 on hepatocyte plasma membrane
8. Histological grading and staging of chronic hepatitis